Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGlaxosmithkline Share News (GSK)

Share Price Information for Glaxosmithkline (GSK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,604.50
Bid: 1,604.00
Ask: 1,604.50
Change: -5.50 (-0.34%)
Spread: 0.50 (0.031%)
Open: 1,611.50
High: 1,615.50
Low: 1,599.50
Prev. Close: 1,610.00
GSK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

BROKER RATINGS SUMMARY: UBS Cuts GlaxoSmithKline To Neutral From Buy

Thu, 14th May 2015 08:38

LONDON (Alliance News) - The following shares received analyst recommendations Thursday morning and Wednesday afternoon:
----------
FTSE 100
----------
UBS CUTS GLAXOSMITHKLINE TO 'NEUTRAL' ('BUY') - PRICE TARGET 1500 (1700) PENCE
----------
NUMIS CUTS EASYJET TO 'ADD' ('BUY') - TARGET 1850 (2100) PENCE
----------
NUMIS RAISES JOHNSON MATTHEY PRICE TARGET TO 3780 (3642) PENCE - 'ADD'
----------
TRADERS: JEFFERIES INITIATES CENTRICA WITH 'BUY'
----------
BERNSTEIN CUTS AB FOODS PRICE TARGET TO 2800 (3000) PENCE - 'MARKET-PERFORM'
----------
NOMURA RAISES SABMILLER PRICE TARGET TO 3600 (3400) PENCE - 'NEUTRAL'
----------
DEUTSCHE BANK RAISES MONDI PLC PRICE TARGET TO 1640 (1510) PENCE - 'BUY'
----------
LIBERUM RAISES BARRATT DEVELOPMENTS PRICE TARGET TO 536 (519) PENCE - 'HOLD'
----------
Numis Cuts ITV To Add From Buy, Price Target Raised To 290p From 275p
----------
FTSE 250
----------
NUMIS RAISES ZOOPLA PROPERTY PRICE TARGET TO 245 (215) PENCE - 'ADD'
----------
JPMORGAN CUTS JOHN WOOD PRICE TARGET TO 497 (505) PENCE - 'UNDERWEIGHT'
----------
UBS RAISES PARAGON GROUP PRICE TARGET TO 512 (450) PENCE - 'BUY'
----------
BERENBERG RAISES HOWDEN JOINERY GROUP PRICE TARGET TO 530 (525) PENCE - 'BUY'
----------
MAIN MARKET AND AIM
----------
NUMIS CUTS CHIME COMMUNICATIONS TO 'ADD' ('BUY') - TARGET 339 (400) PENCE
----------
NUMIS RAISES CENTAUR MEDIA PRICE TARGET TO 90 (84) PENCE - 'BUY'
----------
UBS CUTS OXFORD INSTRUMENTS TO 'NEUTRAL' ('BUY') - TARGET 1150 (950) PENCE
----------
Liberum Raises NewRiver Retail Price Target To 355p From 336p, Reiterates Buy
----------
Cantor Fitzgerald Upgrades Greenko Group To Buy From Hold, Price Target Cut To 82p From 86p
----------
PANMURE INITIATES XP POWER WITH 'BUY' - TARGET 1709 PENCE
----------
By Arvind Bhunjun; arvindbhunjun@alliancenews.com; @ArvindBhunjun

Copyright 2015 Alliance News Limited. All Rights Reserved.

More News
17 Jan 2024 07:31

GSK raises $1.24 bln from latest Haleon stake sale

Jan 17 (Reuters) - GSK has raised 978 million pounds ($1.24 billion) from a discounted sale of a stake in its spun-off consumer healthcare business Haleon, the British drugmaker said on Wednesday.

Read more
16 Jan 2024 17:04

GSK to sell GBP1 billion worth of Haleon shares as trims stake again

(Alliance News) - GSK PLC on Tuesday said it intends to sell around GBP1.00 billion worth of shares in Haleon PLC, as it continues to reduce its shareholding in the Weybridge, Surrey-based consumer healthcare spin-off.

Read more
16 Jan 2024 09:14

LONDON BROKER RATINGS: UBS raises GSK and cuts AstraZeneca

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning:

Read more
16 Jan 2024 08:15

UBS downgrades AstraZeneca to 'sell'

(Sharecast News) - UBS has downgraded AstraZeneca and upgraded rival GSK as part of its latest review of the European pharmaceutical sector.

Read more
16 Jan 2024 07:37

LONDON BRIEFING: UK jobless rate sticks at 4.2% but pay growth slows

(Alliance News) - Stocks in London are called to open lower on Tuesday, following data showing that the UK jobless rate was unchanged at 4.2% as pay growth slowed.

Read more
15 Jan 2024 08:42

Zantac fallout unfairly weighing on GSK, says Shore Capital

(Sharecast News) - Shore Capital has raised its target price and maintained a positive stance on biopharma giant GSK, saying that worries about the potential cost of Zantac litigation are unfairly weighing on the stock.

Read more
10 Jan 2024 09:35

LONDON BROKER RATINGS: BofA cuts Ashtead; UBS likes 3i Group

(Alliance News) - The following London-listed shares received analyst recommendations Wednesday morning and Tuesday:

Read more
10 Jan 2024 08:25

GSK says Nucala gets green light in China for asthma treatment

(Alliance News) - GSK PLC on Wednesday said Nucala has been approved in China for the treatment of severe asthma.

Read more
10 Jan 2024 07:22

GSK's Nucala gets fresh approval in China

(Sharecast News) - GSK announced on Wednesday that the China National Medical Products Administration (NMPA) has granted approval for 'Nucala', or mepolizumab, as an add-on maintenance treatment for severe eosinophilic asthma in adults and adolescents aged 12 years and older.

Read more
9 Jan 2024 16:22

London close: Stocks finish red after choppy session

(Sharecast News) - London stocks had turned back into the red by the close on Tuesday, with recruitment firms and asset managers pacing the declines after some disappointing corporate updates.

Read more
9 Jan 2024 08:03

TOP NEWS: GSK to buy Aiolos Bio for up to USD1.4 billion

(Alliance News) - GSK PLC on Tuesday said it will acquire asthma drug developer Aiolos Bio Inc for USD1 billion upfront, as well as up to USD400 million in certain success-based milestone payments.

Read more
9 Jan 2024 07:16

GSK buys respiratory drug maker Aiolos for $1bn

(Sharecast News) - GSK said it was buying Aiolos, a clinical-stage biopharmaceutical company focused on treatment of respiratory and inflammatory conditions, for up to $1.4bn (£1.1bn).

Read more
8 Jan 2024 23:39

Pfizer to remain aggressive on obesity market after setback

NEW YORK, Jan 8 (Reuters) - Pfizer will remain aggressive in trying to break into the lucrative obesity market, even after dropping a high profile weight-loss drug candidate late last year due to strong side effects, Chief Executive Albert Bourla said on Monday.

Read more
8 Jan 2024 23:00

Pfizer to remain aggressive on obesity market after setback

NEW YORK, Jan 8 (Reuters) - Pfizer will remain aggressive in trying to break into the lucrative obesity market, even after dropping a high profile weight-loss drug candidate late last year due to strong side effects, Chief Executive Albert Bourla said on Monday.

Read more
8 Jan 2024 19:02

Moderna says it hit its 2023 COVID vaccine sales goal

Jan 8 (Reuters) - Moderna on Monday said its 2023 COVID vaccine sales would be around $6.7 billion, coming in above the lower end of its full-year forecast, and reiterated its goal of returning to sales growth in 2025.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.